ITHACA, N.Y.--(BUSINESS WIRE)--

Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntingtons disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntingtons Disease by neutralizing a toxic fragment of the Huntingtin mutant protein in the nucleus of the cell preventing gene dysregulation.

We are extremely excited by these data linking INT41 results to specific molecular events in Huntingtons pathology. INT41 provides a surgical approach to inactivate the event for which a growing body of evidence indicates occurs prior to symptoms and may be the driver of disease progression said Lee Henderson, Ph.D., the CEO of Vybion and a coauthor on the presentation. Vybion is pursuing the completion of preclinical development and expects to begin human clinical trials in the next 18 months.

About Vybion, Inc. Vybion is a development stage Company with proprietary technologies that form the core of our business strategy. Vybion uses proprietary technologies for Intrabody development to treat neurodegenerative diseases such as Huntington's, SBMA and SCA, and for target validation in signal transduction pathways and in multiple therapeutic areas. Vybion is advancing its novel research therapy for Huntingtons disease, INT41, through preclinical development with the aim of initiating clinical studies in the near future.

Read the original here:
Vybion’s Huntington Drug Neutralizes Critical Disease Driver

Comments are closed.